SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hester Biosciences Ltd (HESTERBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524669 NSE: HESTERBIO Pharmaceuticals & Drugs | Small Cap | Hester Biosciences Share Price

₹2,178.65 -14.80 (-0.67%)

As on 02-Jul'26 16:59

Hester Biosciences Ltd (HESTERBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524669 NSE: HESTERBIO Pharmaceuticals & Drugs | Small Cap | Hester Biosciences Share Price

₹2,178.65 -14.80 (-0.67%)

As on 02-Jul'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹1,853 Cr.
Current Price
₹2,178.7
52-Week Low / High
₹1,251 / 2,348
TTM EPS
₹61.2
TTM Sales
₹292 Cr.
Book Value per Share
₹452.8
P/E Ratio
35.57
Lower than its 5-year historical median
Industry PE
49.2
Price to Book (P/B)
4.81
Lower than its 5-year historical median
Price to Sales (P/S)
6.34
In line with its 5-year historical median
EV/EBITDA
24.01
Lower than its 5-year historical median
Dividend Yield
0.5%
Profitability Efficiency
Return on Equity (ROE)
14.39%
Outperforms industry median
Return on Capital Employed (ROCE)
17.02%
Outperforms industry median
Return on Assets (ROA)
9.44%
Operating Profit Margin
23.3%
Net Profit Margin
17.83%
Gross Profit Margin
25%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
1.98%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
33%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
63.63%
Asset Quality
Promoter Holding
53.73%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹377 Cr.
Equity
₹8.5 Cr.
Face Value
₹10
All Time Low / High
₹0.25 / 3375.45

Hester Biosciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Somewhat Undervalued

Price Trend

Strong
Q.1 Is Hester Biosciences Ltd a good quality company?
Hester Biosciences Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Hester Biosciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Hester Biosciences Ltd vs industry peers?
Hester Biosciences Ltd revenue CAGR is 11.08%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Hester Biosciences Ltd?
Promoters hold 53.73% of the Hester Biosciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Hester Biosciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 11.4% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Hester Biosciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % 24.2%26.3%31.2%19.7%23.3%17.3%11.9%9.3%10.6%17%-
Value Creation
Index
0.70.91.20.40.70.2-0.2-0.3-0.20.2-

Growth Parameters

Sales 123135171169208219254285286292292
Sales YoY Gr.-9.3%27%-1%23.1%5.2%15.8%12.3%0.5%2%-
Adj EPS 29.335.850.935.751.645.436.931.537.153.761.2
YoY Gr.-22%42.4%-29.8%44.3%-11.9%-18.7%-14.6%17.6%44.6%-
BVPS (₹) 143.5171.7210.9238.7279.3315.5343.7367.6398.6452.8452.8
Adj Net
Profit
24.930.443.330.443.938.631.426.831.645.752
Cash Flow from Ops. 27.632.336.225.841.115.933.442.96450.9-
Debt/CF from Ops. 1.41.31.11.90.47.74.93.11.61.5-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales 10.1%7%4.8%2%
Adj EPS 7%0.8%13.3%44.6%
BVPS13.6%10.2%9.6%13.6%
Share Price 11.5% -3.3% 8.6% 20.6%

Key Financial Parameters

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity %
22.422.726.615.919.915.311.28.99.712.613.5
Op. Profit
Mgn %
33.436.839.731.134.727.621.516.41823.324.8
Net Profit
Mgn %
20.222.625.3182117.612.49.41115.617.8
Debt to
Equity
0.30.30.20.20.10.50.60.40.30.20.1
Working Cap
Days
217220208261245279292271252239108
Cash Conv.
Cycle
14014013416414516416815213113053

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales123135171169208219254285286292
Operating Expenses + 8285103117136159199238236224
Manufacturing Costs12151819181920282624
Material Costs302329295364801009482
Employee Cost 18222737333948575553
Other Costs 22252932323751546165
Operating Profit 41506853726155475168
Operating Profit Margin (%) 33.3%36.8%39.6%31.1%34.5%27.6%21.5%16.4%17.8%23.2%
Other Income + 12332565512
Exceptional Items 0000-500007
Interest 3245426557
Depreciation 658910101010910
Profit Before Tax 33446041555344374270
Tax 8131610151412101018
Profit After Tax 25314431404032273252
PAT Margin (%) 20.2%22.7%25.6%18.4%19.1%18.0%12.7%9.5%11.1%17.8%
Adjusted EPS (₹)29.335.951.636.746.946.538.031.937.461.2
Dividend Payout Ratio (%)18.10%27.80%21.30%18%21.30%21.50%21%18.80%18.70%18%

Valuation of Hester Biosciences - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 122146179203238268292313339385
Share Capital 9999999999
Reserves 114138171195229260284304331377
Debt +3639323941071411098046
Long Term Debt191511737383795122
Short Term Debt1824213223357302924
Minority Interest0000000000
Trade Payables78814141129303321
Others Liabilities 131820212638849894106
Total Liabilities 178210240277282424546550546557

Fixed Assets

Net Fixed Assets +6167101978784108103105288
Gross Block110121162167165171199204212402
Accumulated Depreciation49546170788791100107114
CWIP 2130014821491711839
Investments 9142841446565656564
Inventories33394860577179695960
Trade Receivables27323345465782868192
Cash Equivalents 111225126525
Others Assets 16162728446457515239
Total Assets 178210240277282424546550546557

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity + 28323626411633436451
PBT 33446041555344374270
Adjustment 97812201215131612
Changes in Working Capital -7-9-16-16-20-33-17416-17
Tax Paid -7-9-16-11-13-16-8-11-10-13
Cash Flow From Investing Activity + -15-26-25-21-4-111-72-21-19-2
Capex 0-21-12-7-4-90-73-22-20-17
Net Investments 0-0-1-21-200000
Others -16-5-12-12-1002115
Cash Flow From Financing Activity + -6-6-20-1-419541-24-46-48
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 6-4-3-1-27312-3-28-31
Interest Paid -3-2-4-4-4-1-10-13-13-7
Dividend Paid -4-6-10-7-6-9-9-7-5-6
Others -47-311-303248-2-1-4
Net Cash Flow 6-0-93-403-2-10

Financial Ratio

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)22.4322.7926.9416.3318.1115.6211.538.989.7714.39
ROCE (%)24.1626.2831.1519.7423.2817.3111.919.2610.5917.02
Asset Turnover Ratio0.740.70.760.650.750.630.530.520.520.53
PAT to CFO Conversion(x)1.121.030.820.841.030.41.031.5920.98
Working Capital Days
Receivable Days7779.1068.9083.4079.1084.5099.30107.50105.90107.80
Inventory Days96.9096.8093117.30102.80105.40106.9094.5080.9074
Payable Days81.3012099.30135.2094.4071.6090.80107121.20118.20

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Hester Biosciences Ltd FAQs

The current trading price of Hester Biosciences on 02-Jul-2026 16:59 is ₹2,178.7.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jul-2026 the market cap of Hester Biosciences stood at ₹1,853.4 Cr

The latest P/E ratio of Hester Biosciences as of 01-Jul-2026 is 35.57.

The latest P/B ratio of Hester Biosciences as of 01-Jul-2026 is 4.81.

The 52-week high of Hester Biosciences is ₹2,347.7 and the 52-week low is ₹1,251.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Hester Biosciences is ₹292 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Hester Biosciences Ltd is a good quality company.

The key valuation ratios of Hester Biosciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Hester Biosciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Hester Biosciences Ltd

Hester Biosciences was incorporated on April 29, 1987 as a Private Limited Company by the name of Hester Pharmaceuticals Limited. It was subsequently converted into a Public Limited Company on November 1, 1993. The company is engaged in the manufacturing of poultry vaccines. The company has been promoted by Rajiv D. Gandhi his brother Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. The company changed its name to the present in 2008.

The company is a 100% biotech company producing animal biologicals. Located near the city of Ahmedabad, in the state of Gujarat, in Western India, Hester has a state-of-the-art facility to produce live and killed (Inactivated) veterinary vaccines.

Production procedures for poultry vaccines based on in-house advanced capabilities are being followed in the areas of virus propagation in specific pathogen-free embryos, tissue culture, batch fermentation of bacteria, lyophilisation and emulsion preparation.

Hester on December 22, 2008 launched a poultry vaccine against Coryza disease in chicken, containing 3 serotypes – A, B & C.

Hester is the first company in India to manufacture the Coryza vaccine with 3 strains as against other companies manufacturing the vaccine with only 2 serotypes - A & C. Coryza disease is of economical importance to poultry farmers as it causes a drop in egg production in laying birds.

Hester currently manufactures 39 types of poultry vaccines against various poultry diseases.

Product range of the company includes:

  • Live Vaccines
  • Killed Vaccines
  • Diagnostic kits &  Seromonitoring services

Achievements/ recognition:

  • GMP and ISO 9001:2000 certified company
You have 3 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: